Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Biotech
Pfizer-backed CellCentric secures $120M for ph. 3 myeloma trial
CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials.
James Waldron
May 19, 2025 9:25am
C4T halts BRAF degrader work to save cash for cemsidomide
May 7, 2025 7:00am
British biotech CellCentric expands to Boston, plans hiring push
Apr 2, 2025 1:53pm
Genmab axes anti-CD38 antibody after losing J&J support
Mar 10, 2025 2:13pm
Exicure buys GPCR's US unit and clinical-stage blood cancer drug
Jan 23, 2025 5:01am
JPM25: AbbVie pens $1B deal for Simcere’s ph. 1 T-cell engager
Jan 13, 2025 10:28am
